Core Viewpoint - Yongtai Bio-B (06978) has announced significant oversubscription in its rights issue, indicating strong investor interest and confidence in the company's future prospects [1][2] Group 1 - The company received valid acceptances for a total of 92.1758 million rights shares, representing approximately 89.56% of the total 103 million rights shares offered [1] - There were 8 valid applications for additional rights shares, totaling 446 million shares, which is about 433.15% of the total rights shares offered [1] - In total, there were 21 valid acceptances and applications for 538 million rights shares, amounting to approximately 522.71% of the total rights shares offered [1] Group 2 - A total of 435 million rights shares were oversubscribed, which is about 422.71% of the total 103 million rights shares offered [2] - The allocation of additional rights shares was made based on a ratio of approximately 2.41% of the number of additional shares applied for, due to insufficient shares to meet all valid applications [2] - There was no prioritization for applications based on existing shareholdings or for consolidating fractional shares into whole shares [2]
永泰生物-B：供股获有效接纳约522.71%